# RDEA3170 Monotherapy in Subjects With Gout

> **NCT01927198** · PHASE2 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 172 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Placebo
- **DRUG:** RDEA3170 5 mg
- **DRUG:** RDEA3170 10 mg
- **DRUG:** RDEA3170 12.5 mg

## Key facts

- **NCT ID:** NCT01927198
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-05
- **Final completion:** 2014-07
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927198, "RDEA3170 Monotherapy in Subjects With Gout". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01927198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*